<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01216618</url>
  </required_header>
  <id_info>
    <org_study_id>G080106/A</org_study_id>
    <nct_id>NCT01216618</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effect of the InsuPatch Device on Insulin Pharmacokinetics in Clamp Studies</brief_title>
  <official_title>Evaluation of the Effect of the InsuPatch Device on Insulin Pharmacokinetics in Clamp Studies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Insuline Medical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Insuline Medical Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective, multi-center, open label, randomized; two-arms cross over study.&#xD;
&#xD;
      This is the test protocol for the InsuPatch device, whose purpose is to improve insulin&#xD;
      delivery into the blood when the insulin is infused using an insulin-infusion pump by&#xD;
      controlled heating of the area surrounding the point of infusion.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fifty five(55) type 1 IDDM subjects in three centers who use the MiniMed paradigm insulin&#xD;
      pump, meeting the inclusion/exclusion criteria as outlined below and who provide written&#xD;
      Informed Consent will be enrolled in the study.&#xD;
&#xD;
      The study will be done with subjects randomized into one of two procedure sequences. Each&#xD;
      subject will undergo 3 procedures (two clamps with the InsuPatch and one clamp without the&#xD;
      InsuPatch) and will thus serve as his/her own control. The same 55 subjects will be&#xD;
      randomized into one sequence or the other. The order of the procedures will be selected&#xD;
      randomly and will be performed both within one month.&#xD;
&#xD;
      There will be six Device visits starting with a screening and randomization visit, 3 clamps&#xD;
      and a completion visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy</measure>
    <time_frame>Up to 5 hours</time_frame>
    <description>Determination of insulin delivery to the blood as measured by Insulin levels in the blood derived from blood samples collected at pre-specified time points during the glucose clamp test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Up to one month</time_frame>
    <description>frequency and severity of all treatment-related adverse events until the completion of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics</measure>
    <time_frame>Up to 5 hours</time_frame>
    <description>Cmax PK which is the highest concentration of insulin reached derived from blood samples collected at pre-specified time points during the glucose clamp test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic</measure>
    <time_frame>Up to 5 hours</time_frame>
    <description>Tmax PD which is the time of highest glucose infusion rate (GIR) derived from blood samples collected during the glucose clamp test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Diabetes Mellitus, Insulin-Dependent</condition>
  <arm_group>
    <arm_group_label>Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject starts with two clamps including device use follows by a clamp without device use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subject starts with clamps without device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>InsuPatch</intervention_name>
    <description>the InsuPatchTM device includes a heating pad and electronics. The heating pad is attached to an existing insulin infusion set by a simple procedure.</description>
    <arm_group_label>Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 18- 65 years old (including = 18 years and =65 years)&#xD;
&#xD;
          2. Gender: men and women&#xD;
&#xD;
          3. BMI: 18-35 kg/m2&#xD;
&#xD;
          4. Type 1 Insulin dependent diabetes using the MiniMed paradigm insulin pumps for at&#xD;
             least six months and using insulin Lispro or Insulin Aspart.&#xD;
&#xD;
          5. Diabetic subjects with HbA1c values below 9.5% (including 9.5%).&#xD;
&#xD;
          6. Subject understands the study requirements and the treatment procedures and has signed&#xD;
             an Informed Consent before any study-specific tests or procedures are performed&#xD;
&#xD;
          7. Subject is willing to comply with all specified follow-up evaluations -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy&#xD;
&#xD;
          2. Breast feeding women.&#xD;
&#xD;
          3. Alcohol addiction&#xD;
&#xD;
          4. Had CABG (Coronary Artery Bypass Graft), are Post MI (Myocardial Infarction) or had&#xD;
             active Ischemic heart disease prior to the study date&#xD;
&#xD;
          5. Had CVA (cardiovascular accident) or TIA (transient ischemic accident) prior to the&#xD;
             study&#xD;
&#xD;
          6. Suffer from uncontrolled Hypertension (blood pressure in mm HG &gt;160 systolic or &gt; 95&#xD;
             diastolic)&#xD;
&#xD;
          7. Low blood hemoglobin concentration &lt;9 g/dL for female and &lt;11g/dL for male.&#xD;
&#xD;
          8. Abnormal kidney and/ or liver function tests. (If any of the liver or kidney function&#xD;
             test parameters are greater than 3 fold normal values.&#xD;
&#xD;
          9. Subjects with Hyperthyroidism or Hypothyroidism with TSH level outside the normal&#xD;
             range, TSH&gt;5.5 mIU/L or TSH&lt;0.4 mIU/L&#xD;
&#xD;
         10. Psychological incompetence&#xD;
&#xD;
         11. Any other clinical condition or history, that seems to be relevant to the principle&#xD;
             investigator to disqualify the participant.&#xD;
&#xD;
         12. Subjects with diminished skin integrity&#xD;
&#xD;
         13. Subjects with heat sensitivity&#xD;
&#xD;
         14. Subjects involved in or planed to participate in other studies&#xD;
&#xD;
         15. Subjects using other drugs therapies to control blood glucose level other than&#xD;
             insulin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mills-Peninsula Health Services</name>
      <address>
        <city>San Mateo</city>
        <state>California</state>
        <zip>94401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Haddasah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.insuline-medical.com</url>
    <description>Sponsor's Official web site</description>
  </link>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>October 5, 2010</study_first_submitted>
  <study_first_submitted_qc>October 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2010</study_first_posted>
  <last_update_submitted>September 3, 2014</last_update_submitted>
  <last_update_submitted_qc>September 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MiniMed paradigm insulin pumps</keyword>
  <keyword>insulin Lispro</keyword>
  <keyword>Insulin Asprt.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

